Back to top
more

Dr. Reddys Laboratories (RDY)

(Real Time Quote from BATS)

$77.95 USD

77.95
86,183

-2.49 (-3.10%)

Updated Jul 16, 2024 12:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 33% (168 out of 250)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

BioMarin (BMRN) Phenylketonuria Gene Therapy on Clinical Hold

by Zacks Equity Research

BioMarin's (BMRN) phase I/II study on gene therapy candidate, BMN 307, has been placed under a clinical hold by the FDA possibly on malignancy concerns.

3 Generic Drug Stocks to Watch Amid Pandemic & Pricing Pressure

by Zacks Equity Research

The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is expected to recede in the second half of 2021. Moreover, stable pricing and improving demand in some countries in 2021 may bode well for RDY, BHC and AMPH.

Amarin (AMRN) Q2 Earnings Top, Vascepa Strong Despite Generics

by Zacks Equity Research

Amarin's (AMRN) Vascepa sales benefit from increased demand in the United States during the second quarter. The drug retains majority market share in its segment amid rising generic competition. Stock up.

Dr. Reddy's (RDY) Q1 Earnings Decline Y/Y, Sales Increase

by Zacks Equity Research

Dr. Reddy's (RDY) earnings decline while sales grow year over year in first-quarter fiscal 2022.

Dr. Reddy's (RDY) Q4 Earnings Decline Y/Y, Sales Increase

by Zacks Equity Research

Dr. Reddy's (RDY) earnings decline while sales grow year over year in fourth-quarter fiscal 2021.

Amarin (AMRN) Q1 Earnings Top, Vascepa Sales Hit by COVID-19

by Zacks Equity Research

Amarin's (AMRN) Vascepa sales get hit by COVID-19 and by severe winter storms and power outages in various areas of the United States. Its cost management plan boost the bottom line. Stock up.

Indrajit Bandyopadhyay headshot

3 Generic Drug Stocks to Watch Amid COVID-Related Recovery

by Indrajit Bandyopadhyay

The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is expected to recede in 2021. Moreover, stable pricing and improving demand in some countries in 2021 may bode well for RDY, BHC and AMPH.

Amarin (AMRN) Q4 Earnings & Revenues Top, Vascepa Sales Solid

by Zacks Equity Research

Amarin's (AMRN) revenue growth in the fourth quarter is attributable to continued demand for its cardiovascular drug, Vascepa.

Dr. Reddy's (RDY) Q3 Earnings Decline Y/Y, Sales Increase

by Zacks Equity Research

Dr. Reddy's (RDY) earnings decline while sales grow year over year in third-quarter fiscal 2021.

Dr. Reddy's (RDY) Ends Kuwait Study on Avigan for COVID-19

by Zacks Equity Research

Dr. Reddy's (RDY) and Global Response Aid FZCO terminate the Avigan study conducted in Kuwait, focused on moderate-to-severe COVID patients in a hospital setting.

Dr. Reddy's (RDY) to Begin Phase III Study on Sputnik Vaccine

by Zacks Equity Research

Dr. Reddy's (RDY) receives approval from the DCGI to conduct a phase III study on the Sputnik V vaccine for the treatment of COVID-19 in India.

Exelixis (EXEL) Reports Preliminary Q4 Results, Business Updates

by Zacks Equity Research

Exelixis (EXEL) provides preliminary results for the fourth quarter and 2020 along with the annual guidance for 2021. It also throws light on anticipated milestones for 2021.

The Zacks Analyst Blog Highlights: Brilliance China, Baidu, Impala and Dr. Reddy's

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Brilliance China, Baidu, Impala and Dr. Reddy's

Urmimala Biswas headshot

4 Emerging Market Stocks to Tap 2021 Economic Rebound

by Urmimala Biswas

Here we discuss four emerging market stocks, BCAUY, BIDU, IMPUY and RDY, which have solid growth prospects for 2021.

Exelixis (EXEL) In-Licenses Aurigene's Compound, Files IND

by Zacks Equity Research

Exelixis (EXEL) exercises an option to in-license Aurigene's novel CDK7 inhibitor and submits an IND to the FDA for evaluating the candidate in a phase I study.

3 Generic Drug Stocks to Watch Amid COVID-Induced Uncertainty

by Zacks Equity Research

The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is difficult to gauge. However, stable pricing and improvement in demand in some countries in 2021 may bode well for RDY, BHC and VTRS.

Amarin's (AMRN) Q3 Earnings Lag, Sales In Line, Stock Down

by Zacks Equity Research

Amarin's (AMRN) revenue growth in the third quarter is attributable to continued demand for its cardiovascular drug, Vascepa. Generic competition for Vascepa seems imminent.

Endo (ENDP) Q3 Earnings & Sales Top Estimates, View Raised

by Zacks Equity Research

Endo's (ENDP) earnings and sales beat estimates in the third quarter. The company raises its annual outlook.

Bausch's (BHC) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Bausch (BHC) reports better-than-expected results for the third quarter as the business shows recovery signs from the COVID-19 pandemic.

Dr. Reddy's (RDY) Q2 Earnings Decline Y/Y, Sales Increase

by Zacks Equity Research

Dr. Reddy's (RDY) earnings decline year over year while sales increase in second-quarter fiscal 2021.

Bausch Acquires License for Myopia Solution from Eyenovia

by Zacks Equity Research

Bausch (BHC) acquires license for an investigational microdose formulation of atropine ophthalmic solution from Eyenovia.

BioMarin (BMRN) Gets FDA Approval for Higher Dose of Palynziq

by Zacks Equity Research

The FDA approves higher dose (60 mg) of BioMarin's (BMRN) Phenylketonuria drug Palynziq injection. The regulatory nod includes the addition of longer-term efficacy data on Palynziq's label.

BioMarin Initiates Gene Therapy Study for Phenylketonuria

by Zacks Equity Research

BioMarin (BMRN), a leader in the phenylketonuria segment, initiates development of its first gene therapy for treating the rare genetic enzyme deficiency disorder.

Dr. Reddy's Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Dr. Reddy's Laboratories.

Dr. Reddy's Settles Revlimid Patent Suit With Bristol Myers

by Zacks Equity Research

Dr. Reddy's (RDY) settles litigation with Bristol Myers relating to patents for Revlimid (lenalidomide) capsules.